JP2024527627A - 線維芽細胞活性化タンパク質阻害剤及びその使用 - Google Patents

線維芽細胞活性化タンパク質阻害剤及びその使用 Download PDF

Info

Publication number
JP2024527627A
JP2024527627A JP2024503606A JP2024503606A JP2024527627A JP 2024527627 A JP2024527627 A JP 2024527627A JP 2024503606 A JP2024503606 A JP 2024503606A JP 2024503606 A JP2024503606 A JP 2024503606A JP 2024527627 A JP2024527627 A JP 2024527627A
Authority
JP
Japan
Prior art keywords
group
nos
compound according
compound
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024503606A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527627A5 (https=
JPWO2023002045A5 (https=
Inventor
オスターカンプ，フランク
ツボラルスキ，ディルク
パシュケ，マティアス
ヘーネ，アイリーン
ワスネル－テシュネル，イェシカ
ハーセ，クリスティアン
ライネケ，ウルリッヒ
スマーリング，クリスティアーネ
ウンゲヴイス，ヤン
ブレデンベック，アンネ
ギブソン，クリストフ
サウペ，イェルン
Original Assignee
スリービー・ファーマシューティカルズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スリービー・ファーマシューティカルズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング filed Critical スリービー・ファーマシューティカルズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Publication of JP2024527627A publication Critical patent/JP2024527627A/ja
Publication of JP2024527627A5 publication Critical patent/JP2024527627A5/ja
Publication of JPWO2023002045A5 publication Critical patent/JPWO2023002045A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024503606A 2021-07-23 2022-07-22 線維芽細胞活性化タンパク質阻害剤及びその使用 Pending JP2024527627A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21187424.3A EP4122499A1 (en) 2021-07-23 2021-07-23 Fibroblast activation protein inhibitors and use thereof
EP21187424.3 2021-07-23
PCT/EP2022/070693 WO2023002045A1 (en) 2021-07-23 2022-07-22 Fibroblast activation protein inhibitors and use thereof

Publications (3)

Publication Number Publication Date
JP2024527627A true JP2024527627A (ja) 2024-07-25
JP2024527627A5 JP2024527627A5 (https=) 2026-01-30
JPWO2023002045A5 JPWO2023002045A5 (https=) 2026-01-30

Family

ID=77042830

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024503606A Pending JP2024527627A (ja) 2021-07-23 2022-07-22 線維芽細胞活性化タンパク質阻害剤及びその使用

Country Status (11)

Country Link
US (1) US20240335569A1 (https=)
EP (2) EP4122499A1 (https=)
JP (1) JP2024527627A (https=)
KR (1) KR20240040092A (https=)
CN (1) CN117769443A (https=)
AU (1) AU2022313521A1 (https=)
CA (1) CA3224514A1 (https=)
CL (1) CL2024000200A1 (https=)
IL (1) IL310306A (https=)
MX (1) MX2024000866A (https=)
WO (1) WO2023002045A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4475900A1 (en) 2022-02-09 2024-12-18 Novartis AG Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent
EP4342890A1 (en) * 2022-09-21 2024-03-27 Erasmus University Rotterdam Medical Center Platform and scaffold for fap targeting agents
WO2025106939A1 (en) * 2023-11-16 2025-05-22 Praxis Biotech LLC Conjugates targeting fibroblast activation protein and uses thereof
CN119604492A (zh) * 2023-12-08 2025-03-11 北京师范大学 一种放射性标记fapi配合物及其制备方法和应用
WO2025167951A1 (zh) * 2024-02-07 2025-08-14 苏州博锐创合医药有限公司 一种成纤维细胞活化蛋白抑制剂
WO2025240871A1 (en) * 2024-05-16 2025-11-20 Purdue Research Foundation Chemically stable keto-amide-based fibroblast activation protein-targeted nanoparticle-based magnetic resonance imaging agent, compositions, and methods of use
CN118978511A (zh) * 2024-08-02 2024-11-19 江苏华益科技有限公司 一种靶向fap化合物及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020083853A1 (de) * 2018-10-24 2020-04-30 Johannes Gutenberg-Universität Mainz Markierungsvorläufer mit quadratsäure-kopplung
WO2020132661A2 (en) * 2018-12-21 2020-06-25 Praxis Biotech LLC Inhibitors of fibroblast activation protein
JP2021500373A (ja) * 2017-10-23 2021-01-07 ザ・ジョンズ・ホプキンス・ユニバーシティ 線維芽細胞活性化タンパク質α（ＦＡＰ−α）を標的とする撮像剤および放射線療法用薬剤
JP2021512949A (ja) * 2018-02-06 2021-05-20 ウニベルジテート ハイデルベルク Ｆａｐ阻害物質

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
CN103370063A (zh) 2010-12-13 2013-10-23 免疫医疗公司 用于改善蛋白质、肽和其他分子的f-18标记的方法和组合物
DE102014115088A1 (de) 2014-10-16 2016-04-21 Sovicell Gmbh Bestimmung von Bindungskonstanten mittels Gleichgewichtsverlagerung

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021500373A (ja) * 2017-10-23 2021-01-07 ザ・ジョンズ・ホプキンス・ユニバーシティ 線維芽細胞活性化タンパク質α（ＦＡＰ−α）を標的とする撮像剤および放射線療法用薬剤
JP2021512949A (ja) * 2018-02-06 2021-05-20 ウニベルジテート ハイデルベルク Ｆａｐ阻害物質
WO2020083853A1 (de) * 2018-10-24 2020-04-30 Johannes Gutenberg-Universität Mainz Markierungsvorläufer mit quadratsäure-kopplung
WO2020132661A2 (en) * 2018-12-21 2020-06-25 Praxis Biotech LLC Inhibitors of fibroblast activation protein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THE JOURNAL OF NUCLEAR MEDICINE, vol. 62, no. 2, JPN6026013323, February 2021 (2021-02-01), pages 160 - 167, ISSN: 0005834972 *

Also Published As

Publication number Publication date
KR20240040092A (ko) 2024-03-27
IL310306A (en) 2024-03-01
AU2022313521A1 (en) 2023-12-14
CA3224514A1 (en) 2023-01-26
EP4122499A1 (en) 2023-01-25
MX2024000866A (es) 2024-02-09
WO2023002045A1 (en) 2023-01-26
EP4373529A1 (en) 2024-05-29
CN117769443A (zh) 2024-03-26
AU2022313521A9 (en) 2024-01-04
CL2024000200A1 (es) 2024-06-14
US20240335569A1 (en) 2024-10-10

Similar Documents

Publication Publication Date Title
JP7783396B2 (ja) 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
JP7801207B2 (ja) 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
JP2024527627A (ja) 線維芽細胞活性化タンパク質阻害剤及びその使用
US20230212549A1 (en) Compounds comprising a fibroblast activation protein ligand and use thereof
US20240115745A1 (en) Compounds comprising a fibroblast activation protein ligand and use thereof
WO2022123462A1 (en) Radiolabelled prostate specific membrane antigen (psma) inhibitors and use thereof
AU2022410422A1 (en) Carbonic anhydrase ix ligands
RU2836270C2 (ru) Соединения, содержащие лиганд белка активации фибробластов, и их применение
KR20250057886A (ko) 전립선 특이적 막 항원 (psma) 리간드 및 그의 용도
TW202334177A (zh) 包含纖維母細胞活化蛋白配體之化合物和彼之用途

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260122

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260312

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260407